Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amniotic Fluid Eye Drops for Ocular Chronic GVHD
NCT03298815Phase 2Completed
- Sponsor
- University of Utah
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Classical Binding Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amniotic fluid eye drops in graft versus host disease (GVHD), sponsored by University of Utah. Primary endpoint: Overall Response Rate at 30 days. Started Dec 2019; status: completed.
02
Drugs
amniotic fluid eye drops
03
Conditions
graft versus host disease (GVHD)
Beyond the preview
Go deeper on NCT03298815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298815.